Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
News reports over the past 2 years have transformed a relatively uncommon procedure, endoscopic retrograde cholangiopancreatography (ERCP), into a household name at the center of a widespread “superbug” outbreak. The bacteria being transmitted between patients via ERCP, carbapenem-resistant Enterobacteriaceae (CRE), are frightening because of their resistance to all (or nearly all) currently available antibiotics. Owing to the associated significant mortality rate and their ability to transmit antibiotic resistance to other bacteria, the director of the Centers for Disease Control and Prevention referred to CRE as “nightmare bacteria” (http://www.cdc.gov/media/dpk/2013/dpk-vs-hai.html). Thus, the current national attention focusing on the transmission of CRE through duodenoscopes, the device used to perform ERCP, is not simply media-created hyperbole but, instead, is a deafening wake-up call. Surgeons and physicians should understand the issues pertaining to these iatrogenic infections, should oversee efforts to improve endoscopic reprocessing, should try to decrease the nonindicated use of ERCP, and should help educate patients.
Keswani RN, Soper NJ. Endoscopes and the “Superbug” Outbreak. JAMA Surg. 2015;150(9):831–832. doi:10.1001/jamasurg.2015.1255
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: